Laura Gouzien

Laura Gouzien

Auto-generated profile, based on publicly available information

Laura Gouzien

Institut Pasteur, Paris Cité University, National Reference Center for Invasives Mycoses and Antifungals, Mycology Department, Paris, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
LGLaura Gouzien
Laura Gouzien
DCDidier Che
Didier Che
SCSophie Cassaing
Sophie Cassaing
OLOlivier Lortholary
Olivier Lortholary
VLValérie Letscher-Bru
Valérie Letscher-Bru
Fanny LanternierFanny Lanternier
Fanny Lanternier
Mucormycosis is a deadly invasive fungal infection recently included in the WHO priority pathogen list. Here we sought to describe epidemiological trends of mucormycosis in France, and to evaluate factors associated with mortality. From 2012 to 2022, we implemented a nationwide prospective surveillance programme for mucormycosis in France, focusing on epidemiology, species, seasonal variations. Factors associated with 3-month mortality were studied by univariable and multivariable logistic regression. Among 550 cases of mucormycosis, the main underlying conditions were haematological malignancy (HM, 65.1%, 358/550), trauma (8%, 44/550), diabetes (7.5%, 41/550) and solid-organ transplants (6.5%, 36/550). Site of infection was pulmonary in 52.4% (288/550), rhinocerebral in 14.5% (80/550), and cutaneo-articular in 17.1% (94/550). Main species identified were Rhizopus arrhizus (21%, 67/316), Rhizopus microsporus (13.6%, 43/316), Lichtheimia corymbifera and Mucor circinelloides (13.3%, 42/316 each), Rhizomucor pusillus (12%, 38/316), and Lichtheimia ramosa (10.8%, 34/316). We found associations between underlying condition, site of infection, and infecting species, including a previously undescribed triad of trauma, cutaneo-articular localisations, and L. ramosa/M. circinelloides. Diagnostic contribution of Polymerase Chain Reaction (PCR) increased from 16% (4/25) in 2012 to 91% (61/67) in 2022, with more than 50% of diagnoses relying solely on PCR in 2022. We also found seasonal variations with relatively more cases in autumn. Ninety-day mortality was 55.8% (276/495). Independent prognostic factors were age, diagnosis in Intensive Care Unit (ICU), and HM while diagnosis after 2015 (i.e. large implementation of PCR) and surgery were associated with reduced mortality. This study reveals major mucormycosis epidemiological changes in France, with a large predominance of HM patients, and a parallel between PCR multicentre implementation and improved prognosis. We also evidence new associations between species, localisations and risk factors, as well as seasonal variations. Recurrent financial support from Santé Publique France and 10.13039/501100003762 Institut Pasteur .

1 June 2021 in Infectious Diseases Now
Verified
Journal Article
Closed access
LGLaura Gouzien
Laura Gouzien
TCTheophile Cocherie
Theophile Cocherie
OEOdile Eloy
Odile Eloy
SLStephane Legriel
Stephane Legriel
JBJean-Pierre Bedos
Jean-Pierre Bedos
FBFabrice Bruneel
Fabrice Bruneel